HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Hoth Therapeutics (NASDAQ:HOTH) and maintained a $4 price target.
July 22, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating on Hoth Therapeutics and maintained a $4 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $4 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100